Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anxiety Disorders Therapy
Reports from University of California add new data to research in anxiety disorders therapy
May 16th, 2008
Scientists discuss in 'A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers' new findings in anxiety disorders. According to a study from the United States, "Emerging evidence suggests that dopaminergic and serotonergic functioning are altered in pathological gamblers; yet, there are no FDA-approved medications for pathological gambling and there have only been a limited number of clinical trials that have been conducted. Olanzapine was identified as a candidate medication for pathological gamblers because it modifies both dopaminergic and serotonergic function." "Moreover, preliminary studies have shown that...
Source: Food & Drug Law Weekly (2008-05-16)
|
